Mirafit fbcx reduces human body absorption of consumed fat

Published on October 28, 2009 at 2:03 AM · No Comments

A scientific study to be presented today at the annual meeting of The Obesity Society will confirm significant weight loss using the pill mirafit fbcx®. Dr. K-L Catherine Jen and Dr. Joseph Artiss, principals at ArtJen Complexus USA, LLC, will present these clinical study findings today, October 27, at The Obesity Society 2009 annual scientific meeting at the Marriott Wardman Park Hotel in Washington, D.C., The Obesity Society's 27th annual scientific meeting.

According to Drs. Jen and Artiss, "Mirafit fbcx® is a soluble fiber derived from corn that reduces human body absorption of consumed fat. Taken as directed, six tablets a day will reduce caloric absorption from 2,000 kilocalories/day to 1,500. This is equivalent to approximately 50-60 percent of fat or 25-30 percent of calories from the typical American diet. Five hundred kilocalories per day becomes 3,500 kilocalories per week, which equates to a weight loss of about 1-1 1/2 pounds per week."

How it Works

Mirafit fbcx is a naturally occurring, soluble fiber that forms a very stable complex or emulsion with fat. Scientific research shows this stable complex appears to prevent the digestive enzyme lipase from breaking down dietary fat in the small intestine, thus preventing it from being absorbed into the blood stream. This, in turn, reduces the number of calories that are absorbed and lowers blood lipid (fat) levels. In contrast to some pharmaceutical therapies, the natural fiber of fbcx® shows no undesirable side effects because the undigested fat remains bound as it passes through the intestines.

"Mirafit fbcx binds and eliminates nine times its own weight in dietary fat -- triglycerides. One gram (one tablet) of fbcx binds 9 grams (81 calories) of fat, thus preventing absorption of a significant portion of fat consumed," said Dr. Jen.

Current Clinical Study

The recently completed clinical study, conducted at the University of California, Davis, involves overweight, but not obese non-diabetic individuals. This investigation was intended to confirm the effects of mirafit fbcx on weight management and blood lipid levels as they have been implicated in the development and pathogenesis of numerous disease states, including type 2 diabetes and cardiovascular disease. Twenty-nine healthy adults (age: 43.9+/-13.3 yrs, 8 males) with a stable body weight in the previous month participated in this study. The mean BMI was 27.1 +/-2.1kg/m2 at the beginning of this double-blind, one-month crossover study.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment